DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages

Pharmacogenomics in dermatology

Author: Dr Matthew Howard, Clinic/Research Fellow, Victorian Melanoma Service, Melbourne, VIC, Australia. DermNet NZ Editor in Chief: Adjunct A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell. January 2020.


What is pharmacogenomics?

Pharmacogenomics aims to provide an understanding of how a patient’s whole genome influences their individual response to therapeutics. This field of research combines knowledge from the fields of:

  • Pharmacodynamics (the science of a medicine’s mode of action)
  • Pharmacokinetics (the study of how medications are absorbed, distributed, metabolised, and excreted in the body)
  • The genetic understanding of polymorphisms [1].

Often pharmacogenetics is used interchangeably with pharmacogenomics. However, pharmacogenetics refers to how mutations in a single gene can alter the response to a single medication [1].

Why is pharmacogenomics important?

The interest in pharmacogenomics, pharmacogenetics, and personalised medicine has arisen because of a recent statistic that only about half of the patients given recommended standard doses of many medications will receive the desired therapeutic benefit [2]. Some of this variation in response to medications is attributed to genetic differences in the mechanisms responsible for the pharmacokinetics and pharmacodynamics [3].

Much research has been devoted to the pharmacogenetics of phase 1 metabolism enzymes, particularly the Cytochrome P450 (CYP450) system.

  • Approximately 50% of drug elimination from the body is due to the CYP450 system [4].
  • The CYP450 system is concentrated in the liver with over 57 functional unique enzymes [5].
  • Genetic polymorphisms — the sequential differences in nucleic base structure — are especially frequent in the CYP1A2, 2C9, 2C19, 2D6 and 3A4/5 enzyme genes; the average CYP enzyme has over 10 nonsynonymous single nucleotide polymorphisms (SNPs) [3].
  • Interethnic studies have found that Africans, Asians, and Caucasians have stark differences in their frequency of CYP450 alleles [6].

This variation in the nuclear base sequence of genes (the alleles) can alter the action and efficiency of the CYP450 enzymes.

  • Extensive metabolisers achieve subtherapeutic medication levels and treatment failure.
  • Poor metabolisers are at risk of toxicity.
  • Normal metabolisers possess the wild type gene and have normal metabolic function [7].

Some medications are prodrugs; their active form is the metabolite of the administered compound. In this case:

  • Extensive metabolisers result in excessive production of the active metabolite
  • Poor metabolisers may not produce active metabolite [7].

Risks to the patient are heightened for medications with a narrow therapeutic index.

Pharmacogenetic testing to identify variant metabolic genes can:

  • Identify individuals who will benefit more from some medicines than others
  • Improve the effectiveness of dosing
  • Reduce healthcare expenditure [8].

Over half of the drugs that are commonly implicated in adverse effects are major substrates of enzymes that have a mutant form of the gene that poorly metabolises the medication [9].

  • Iatrogenic events caused by toxicity or treatment failure lead to greater healthcare costs due to increased patient hospitalisation rates and length of stay [10].
  • Adverse events in Australia cause up to 4% of total hospital admissions, increasing to up to 30% in those aged over 75, and cost the government an estimated $500 million dollars (AUD) per year [10].
  • Adverse events have doubled in the USA hospital system in the period of 1998–2005 and account for approximately 100,000 deaths per year [11].

Pharmacogenetic testing may also help the process of drug discovery if drug interactions and adverse effects can be predicted, limiting the use of a new drug to those who are low risk of such events [12].

Typically, a laboratory may only test a limited number of alleles and enzymes.

How do pharmacogenomics and personalised medicine relate to dermatology?

Drugs with a narrow therapeutic index used in dermatology include immunosuppressants such as tacrolimus, mycophenolate, and ciclosporin. Other examples of the application of pharmacogenomics to dermatology follow.

BRAF inhibitors

Effective targeted therapy of metastatic melanoma using BRAF inhibitors (eg, vemurafenib, dabrafenib) requires molecular pathology demonstrating the specific BRAF V600 mutation. BRAF inhibitors can actually enhance MAPK expression in those with wild type BRAF [13,14].

Methotrexate

The metabolism of methotrexate is complex. Mutations of the key metabolic enzymes for methotrexate, thymidylate synthetase (TS) and methylenetetrahydrofolate reductase (MTHR), are associated with increased toxicity and decreased efficacy in rheumatological indications. Similar issues are likely in the dermatological use of methotrexate [15–17].

Azathioprine

The current standard of care is to test patients for thiopurine methyltransferase (TPMT) activity prior to prescribing azathioprine. This is to evaluate the patient’s capacity to metabolise the drug. There are many alleles that cause low TPMT activity, and patients with low activity are at significantly increased risk for gastrointestinal toxicity or myelosuppression from azathioprine [18].

Ciclosporin/tacrolimus

A polymorphism in the CYP3A5 gene has been associated with increased and decreased bioavailability to ciclosporin and tacrolimus respectively [19,20].

Dapsone

There is an increased risk of haemolytic anaemia and neurotoxicity from dapsone in slow acetylators [21].

Cutaneous adverse drug reactions

The slow-acetylator genotype of NAT2 is a risk factor for sulphonamide-induced toxic epidermal necrolysis/Stevens-Johnson syndrome (TEN/SJS) [22].

Those who are heterozygous or homozygous for HLA-B*1502 and of Chinese or Asian ancestry are at risk of carbamazepine-induced TEN/SJS [23].

The HLA-A*31:01 allele has been associated (although less strongly) with severe cutaneous adverse reactions to carbamazepine in Caucasian populations [23].

The risk of severe cutaneous adverse reactions to allopurinol is greatly increased in Chinese and Thai persons, as well as Koreans with HLA-B*58:01 [24].

Vismodegib

The sonic hedgehog (SHH) pathway inhibitor, vismodegib, is effective for basal cell carcinomas (BCCs) with mutations in the SHH pathway such as PTCH1 and SMO (which occur in 70 and 10–20% of BCCs respectively) [25].

Vitamin D analogues

The A and T alleles of the A-1012G polymorphism of the vitamin D receptor gene are associated with an improved response of psoriasis to topical calcipotriol [26].

Biologics

Individuals with tumour necrosis factor-alpha (TNF-α) receptor or promoter mutations can have either an increased or decreased response to TNF-α inhibitors [27].

HLA-C:06:02 is a marker of the response of psoriasis to ustekinumab, with various interleukin polymorphisms potentially altering the effect of other biologics [28].

See smartphone apps to check your skin.
[Sponsored content]

 

Related information

 

References

  1. Pincelli C, Pignatti M, Borroni RG. Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy. Exp Dermatol 2009; 18: 337–49. PubMed
  2. Gurney H. I don't underdose my patients...do I? Lancet Oncol 2005; 6: 637–8. PubMed
  3. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41: 89–295. PubMed
  4. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Eng J Med 2005; 352: 2211–21. PubMed
  5. Nelson DR, Zeldin DC, Hoffman SMG, Maltais LJ, Waine HM, Nebert DW. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 2004; 14: 1–18. PubMed
  6. Suarez-Kurtz G. Pharmacogenomics in admixed populations. Trends Pharmacol Sci 2005; 26: 196–201. PubMed
  7. Crettol S, Petrovic N, Murray M. Pharmacogenetics of Phase I and Phase II Drug Metabolism. Curr Pharm Des 2010; 16: 204–19. PubMed
  8. Somogy A. Evolution of pharmacogenomics. Proc Western Pharmacol Soc 2008; 51: 1–4. PubMed
  9. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001; 286: 2270–9. PubMed
  10. Runciman WB, Roughead EE, Semple SJ, Adams RJ. Adverse drug events and medication errors in Australia. Int J Qual Health Care 2003; 15(S1): i49–i59. PubMed
  11. Ingelman-Sundberg M, Sim SC. Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. Biochem Biophys Res Commun 2010; 396: 90–4. PubMed
  12. Andersson T, Flockhart DA, Goldstein DB, et al. Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther 2005; 78: 559–81. PubMed
  13. Long G, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371: 1877–88. PubMed
  14. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431–5. PubMed
  15. Campalani E, Arenas M, Marinaki A, Lewis C, Barker J, Smith C. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol 2007; 127: 1860–7. PubMed
  16. Fisher MC, Cronstein BN. Meta-analysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 2009; 36: 539–45. PubMed
  17. Dervieux T, Furst D, Lein D, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 2005; 64: 1180–5. PubMed
  18. Newman W, Payne K, Tricker K, et al. A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics 2011; 12: 815–26. PubMed
  19. Tavira B, Coto E, Díaz-Corte C, et al. Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. Clin Chem Lab Med 2011; 49: 825–33. PubMed
  20. Zhu H, Yuan S, Fang Y, Sun X, Kong H, Ge W. The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis. Pharmacogenomics J 2011; 11: 237–46. PubMed
  21. Butcher N, Boukouvala S, Sim E, Minchin R. Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J 2002; 2: 30–42. PubMed
  22. Wolkenstein P, Carrière V, Charue D, et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995; 5: 255–8. PubMed
  23. Hung S, Chung W, Jee S, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16: 297–306. PubMed
  24. Hung S, Chung W, Liou L, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102: 4134–9. PubMed
  25. De Zwaan S, Haass N. Genetics of basal cell carcinoma. Australas J Dermatol 2010; 51: 81–92. PubMed
  26. Halsall J, Osborne J, Pringle J, Hutchinson P. Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis. Pharmacogenet Genomics 2005; 15: 349–55. PubMed
  27. Lacaná E, Amur S, Mummanneni P, Zhao H, Frueh F. The emerging role of pharmacogenomics in biologics. Clin Pharmacol Ther 2007; 82: 466–71. PubMed
  28. Ovejero-Benito M, Muñoz-Aceituno E, Reolid A, Saiz-Rodríguez M, Abad-Santos F, Daudén E. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis. Am J Clin Dermatol 2018; 19: 209–22. PubMed

On DermNet NZ

Other websites

Books about skin diseases